Nathalia Sernizon Guimarães

Dr. Nathalia Sernizon Guimarães

Institute of Collective Health, Federal University of Bahia, Salvador, Bahia, 30120-016, Brazil
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2022 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
NGNathalia Sernizon Guimarães
Nathalia Sernizon Guimarães
AFAndrêa J.F. Ferreira
Andrêa J.F. Ferreira
RSRita de Cássia Ribeiro Silva
Rita de Cássia Ribeiro Silva
APAdelzon Assis de Paula
Adelzon Assis de Paula
CLCinthia Soares Lisboa
Cinthia Soares Lisboa
MBMaurício Lima Barreto
Maurício Lima Barreto

4 January 2025 in Foods
Verified
Journal Article
Open access
PDF file
Renata Puppin ZandonadiRenata Puppin Zandonadi
Renata Puppin Zandonadi
MRMaíra Catharina Ramos
Maíra Catharina Ramos
FEFlavia Tavares Silva Elias
Flavia Tavares Silva Elias
NGNathalia Sernizon Guimarães
Nathalia Sernizon Guimarães
This scoping review aims to understand the cell-based meat production process, including the regulations, potential hazards, and critical points of this production. This review includes studies on cultured meat production processes, health hazards, and regulatory guidelines, excluding those without hazard analysis, incomplete texts, or studies published before 2013. The search was performed in eight electronic databases (MEDLINE, Web of Science, Embase, Cochrane Library, Scopus, LILACS, and Google Scholar) using MeSH terms and adaptations for each database. The search for local studies on regulations and guideline documents was complemented by a manual search on the websites of governments and regulatory agencies from different regions (e.g., FDA, FAO, EFSA, USDA, Health Canada, EC, EU, ANVISA/Brazil, MAPA/Brazil, FSANZ, and SFA). This step involved reading full texts to confirm eligibility and extract key data, including author, year, country, study design, objectives, results, cultured meat protocols, health hazards, and hazard control measures, followed by data analysis. A comprehensive search of the databases yielded 1185 studies and 46 regulatory or guidance documents. After removing duplicate studies and applying eligibility criteria to titles, abstracts and full texts, 35 studies and 45 regulatory or guidance documents were included. The cultured meat production protocols are well-established, highlighting potential hazards and critical control points. Although guidance documents and regulations are limited, they are expanding globally. The development and commercialization of cultured meat require clear, and up-to-date regulations and supervision, which are being studied and formulated by regulatory agencies worldwide. Cultured meat production presents some potential hazards (chemical, biological, and physical) that require food safety considerations: (i) genetic stability of cells/cell lines; (ii) microbiological hazards related to cell lines; (iii) exposure to substances used in the production process; (iv) toxicity and allergenicity of the product or its component for the population; (v) post-harvest microbiological contamination; (vi) chemical contamination/residue levels; and (vii) nutritional aspects/risks. Currently, no standardized testing approach exists for cultured meat. However, effective hazard and safety assessment strategies, such as HACCP combined with best practices, should be implemented throughout the production process.

23 July 2022 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MMMilena Soriano Marcolino
Milena Soriano Marcolino
KMKarina Cardoso Meira
Karina Cardoso Meira
NGNathalia Sernizon Guimarães
Nathalia Sernizon Guimarães
PMPaula Perdigão Motta
Paula Perdigão Motta
VCVictor Schulthais Chagas
Victor Schulthais Chagas
PZPatrícia Klarmann Ziegelmann
Patrícia Klarmann Ziegelmann
Background: The role of ivermectin in the treatment of COVID-19 is still under debate, yet the drug has been widely used in some parts of the world, as shown by impressive market data. The available body of evidence may have changed over the last months, as studies have been retracted and “standards of care” (SOC) used in control groups have changed with rapidly evolving knowledge on COVID-19. This review aims to summarize and critically appraise the evidence of randomized controlled trials (RCTs) of ivermectin, assessing clinical outcomes in COVID-19 patients. Methods: RCTs evaluating the effects of ivermectin in adult patients with COVID-19 were searched through June 22, 2022, in four databases, L.OVE platform, clinical trial registries and pre-prints platforms. Primary endpoints included all-cause mortality and invasive ventilation requirement. Secondary endpoint was the occurrence of adverse events. Risk of bias was evaluated using the Cochrane Risk of Bias 2.0 tool. Meta-analysis included only studies which compared ivermectin to placebo or SOC. Random-effects were used to pool the risk ratios (RRs) of individual trials. The quality of evidence was evaluated using GRADE. The protocol was register in PROSPERO (CRD42021257471). Results: Twenty-five RCTs fulfilled inclusion criteria (n = 6310). Of those, 14 compared ivermectin with placebo, in night ivermectin associated with SOC was compared to SOC and two studies compared ivermectin to an active comparator. Most RCTs had some concerns or high risk of bias, mostly due to lack of concealment of the randomization sequence and allocation, lack of blinding and high number of missing cases. Ivermectin did not show an effect in reducing mortality (RR = 0.76; 95%CI: 0.52–1.11) or mechanical ventilation (RR = 0.74; 95%CI: 0.48–1.16). This effect was consistent when comparing ivermectin vs. placebo, and ivermectin associated with SOC vs. SOC, as well as in sensitivity analysis. Additionally, there was very low quality of evidence regarding adverse effects (RR = 1.07; 95%CI: 0.84–1.35). Conclusions: The evidence suggests that ivermectin does not reduce mortality risk and the risk of mechanical ventilation requirement. Although we did not observe an increase in the risk of adverse effects, the evidence is very uncertain regarding this endpoint.

2 January 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
NGNathalia Sernizon Guimarães
Nathalia Sernizon Guimarães
JJJulliane Joviano-Santos
Julliane Joviano-Santos
MRMarcela Gomes Reis
Marcela Gomes Reis
RCRoberta Rayra Martins Chaves
Roberta Rayra Martins Chaves

5 December 2023 in Obesity Medicine
Verified
Journal Article
Closed access
MRMarcela Gomes Reis
Marcela Gomes Reis
LMLuíz Felipe Guimarães G. Moreira
Luíz Felipe Guimarães G. Moreira
LCLuiza Siqueira Veloso de Andrade Carvalho
Luiza Siqueira Veloso de Andrade Carvalho
CCCaroline Tianeze de Castro
Caroline Tianeze de Castro
RVRenata Adrielle Lima Vieira
Renata Adrielle Lima Vieira
NGNathalia Sernizon Guimarães
Nathalia Sernizon Guimarães

1 June 2023 in The Lancet HIV
Verified
Journal Article
Closed access
NGNathalia Sernizon Guimarães
Nathalia Sernizon Guimarães
LMLaio Magno
Laio Magno
APAdelzon Assis de Paula
Adelzon Assis de Paula
MSMiriam Silliman
Miriam Silliman
RARodrigo Volmir Rezende Anderle
Rodrigo Volmir Rezende Anderle
IDInês Dourado
Inês Dourado